REVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.

Size: px
Start display at page:

Download "REVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER."

Transcription

1 REVOLUTIONARY. Are recurrent bacterial infections a frustration in your practice? WE HAVE FOUND THE ANSWER. MMinimum inimizing BBiofilm EEradication C oncentration Concentration

2 WHY BIOFILM SUSCEPTIBILITY TESTING? With the advancement of antibiotics, bacteria have evolved out of sheer survival. While medicine has continued to make strides in this area, we have found ourselves at a place where we are playing catch up to the bacteria. Considering the extensive involvement of biofilms in infections and diseases in human (medicine), biofilms are responsible for a wide variety of infections in veterinary medicine. (Clutterbuck et al., 2007) New tools are required for the prevention, treatment and diagnosis of pathogens that form biofilms during the infection process, because biofilms have unique properties that are absent in planktonic cells. (Murphy et al., 2009) DID YOU KNOW? As many as 80% of infections are caused by Biofilms, hence the ineffectiveness of treating such chronic cases with MIC results alone. The becscreentm Antimicrobial Susceptibility Test provides insight to bacterial vulnerability above and beyond current MIC testing, analyzing the bacteria in its biofilm state. This groundbreaking technology is now available through Spectrum Labs. For the first time ever, this technology allows us to grow the bacteria in our lab in its Biofilm state rather than in a Planktonic state. This allows us to more effectively assess infections and provide antibiotic treatment to prevent these infections from coming back. Additionally, this assay also reduces antibiotic usage and future bacterial resistancy by allowing Veterinarians to utilize the correct antibiotics and dosage the first time.

3 IMPORTANT ANTIBIOTIC INFORMATION Our antibiotic panels have been developed over the course of several years to contain the most up to date and frequently used antibiotics in veterinary medicine. In the event any of our antibiotics become outdated or antiquated, we retain the ability to upgrade our panels at any time, thus ensuring you the highest quality results possible. Our most current antibiotic panels are: MBEC Gram Positive Antibiotics: Amoxicillin Ampicillin Azithromycin Cefazolin Cefovecin Cefpodoxime Ceftiofur Sodium Chloramphenicol Ciprofloxacin Clindamycin Doxycycline Enrofloxacin Erythromycin Gentamicin Sulfate Marbofloxacin Minocycline Orbifloxacin Oxacillin Sodium Rifampin Tetracycline Trimethoprim + Sulfamethoxazole Vancomycin (+) MBEC Gram Negative Antibiotics: Amikacin Amoxicillin + Clavulanate Ampicillin Azithromycin Cefazolin Cefovecin Cefpodoxime Ceftiofur Sodium Chloramphenicol Ciprofloxacin Doxycycline Enrofloxacin Gentamicin Sulfate Imipenem Marbofloxacin Minocycline Orbifloxacin Piperacillin Tetracycline Tobramycin Sulfate Ticarcillin Clavulanate Trimethoprim + Sulfamethoxazole ( - ) IMPROVED QUALITY OF LIFE FOR PETS contact us (800)

4 COMBINATION ANTIBIOTIC INFORMATION MBEC Gram Positive COMBINATION Antibiotics: Amoxicillin/Clavulanate + Linezolid Ampicillin/Sulbactam + Clindamycin Chloramphenicol + Enrofloxacin Chloramphenicol + Gentamicin Clindamycin + Ceftriaxone Doxycycline + Clindamycin Enrofloxacin + Doxycylcine Gentamicin + Amoxicillin/Clavulanate Gentamicin + Ampicillin/Sulbactam Gentamicin + Ceftriaxone Gentamicin + Clindamicin Gentamicin + Doxycycline Gentmaicin + Enrofloxacin Gentamicin + Linezolid Gentamicin + Marbofloxacin Gentamicin + Minocycline Linezolid + Doxycycline Linezolid + Marbofloxacin Marbofloxacin + Ampicillin/Sulbactam Marbofloxacin + Ceftriaxone Minocycline + Ampicillin/Sulbactam Minocycline + Ceftriaxone Minocycline + Enrofloxacin Trimethoprim/Sulfamethoxazole + Ampicillin/Sulbactam Trimethoprim/Sulfamethoxazole + Ceftriaxone Trimethoprim/Sulfamethoxazole + Clindamycin Trimethoprim/Sulfamethoxazole + Doxycycline Trimethoprim/Sulfamethoxazole + Enrofloxacin Trimethoprim/Sulfamethoxazole + Gentamicin Trimethoprim/Sulfamethoxazole + Linezolid Trimethoprim/Sulfamethoxazole + Marbofloxacin Trimethoprim/Sulfamethoxazole + Minocycline Vancomycin + Amoxicillin/Clavulanate Vancomycin + Ampicillin/Sulbactam Vancomycin + Gentamicin Chloramphenicol + Trimethoprim/Sulfamethoxazole Chloramphenicol + Linezolid Chloramphenicol + Clindamycin Chloramphenicol + Marbofloxacin Clindamycin + Vancomycin Clindamycin + Marbofloxacin Clindamycin + Enrofloxacin Clindamycin + Minocycline Cefovecin + Trimethoprim/Sulfamethoxazole Cefovecin + Linezolid Cefovecin + Clindamycin Cefovecin + Gentamicin (+) COMBINATION MBEC Gram Negative COMBINATION Antibiotics: Amoxicillin/Clavulanate + Azithromycin Amoxicillin/Clavulanate + Chloramphenicol Amoxicillin/Clavulanate + Orbifloxacin Amoxicillin/Clavulanate + Trimethoprim/Sulfamethoxazole Ampicillin + Azithromycin Ampicillin + Doxycycline Ampicillin + Minocycline Ampicillin + Orbifloxacin Ampicillin + Trimethoprim/Sulfamethoxazole Azithromycin + Imipenem Ceftazidime + Azithromycin Ceftazidime + Doxycycline Ceftazidime + Minocycline Ceftazidime + Orbifloxacin Ceftazidime + Trimethoprim/Sulfamethoxazole Chloramphenicol + Orbifloxacin Chloramphenicol + Trimethoprim/Sulfamethoxazole Doxycycline + Orbifloxacin Doxycycline + Trimethoprim/Sulfamethoxazole Gentamicin + Amoxicillin/Clavulanate Gentamicin + Ampicillin Gentamicin + Ceftazidime Gentamicin + Doxycycline Gentamicin + Imipenem Gentamicin + Minocycline Gentamicin + Orbifloxacin Gentamicin + Trimethoprim/Sulfamethoxazole Minocycline + Orbifloxacin Minocycline + Trimethoprim/Sulfamethoxazole Orbifloxacin + Imipenem Trimethoprim/Sulfamethoxazole + Azithromycin Trimethoprim/Sulfamethoxazole + Imipenem Trimethoprim/Sulfamethoxazole + Orbifloxacin Ceftazidime + Gentamicin + Orbifloxacin Imipenem + Gentamicin + Orbifloxacin ( - ) COMBINATION contact us (800)

5 2801 S. 35TH ST, PHOENIX, AZ (480) l (800) FAX: (480) BACTERIAL SUSCEPTIBILITY ORDER FORM Veterinarian: Specimen No: For Office Use Only: Date Rcvd: Clinic: Address: City: State Zip Phone: ( ) Fax: ( ) Receive results via within 7-10 days depending on growth pattern; full results booklet to follow via mail q Check Enclosed Animal s Name: Owner s Name: Breed: Age: q Bill on receipt of results Date: TESTING PANEL OPTIONS PLEASE CHECK APPROPRIATE BOX PLEASE NOTE: ACTIVE INFECTION REQUIRED; DISCONTINUE ANTIBIOTICS 7-10 DAYS PRIOR TO SWABBING. TOTAL COST MBEC PANEL (Minimum Biofilm Eradication Concentration) $60.00* Including ID/MIC for chronic recurring infections and combination antibiotic treatment options. per swab Please indicate which of the following antibiotics the patient has previously been treated with: q Amoxicillin q Ampicillin q Amikacin q Azithromycin q Cefazolin q Cefovecin q Cefpodoxime q Ceftiofur Sodium q Chloramphenicol q Ciprofloxacin q Clindamycin q Doxycycline q Enrofloxacin q Erythromycin q Gentamicin Sulfate q Imipenem q Marbofloxacin q Minocycline q Orbifloxacin q Oxacillin Sodium q Piperacillin q Rifampin q Sulfamethoxazole q Tetracycline q Ticarcillin Clavulanate q Tobramycin Sulfate q Trimethoprim q Vancomycin In the event there is no growth on any culture you will only be billed $30.00 Current as of form: BF2014

6 PATIENT HISTORY FORM Veterinarian: Animal s Name: Breed: Clinic: Owner s Name: Age: Date: 1. Where was the swab taken? q ear q skin q interdigital q urine q open wound q compound fracture q bone graft q gums q Other: 2. Please describe the condition of swab site (i.e. redness, swelling, etc). 3. Has any previous testing been done? If so where? When? 4. Has the patient ever received treatment? q yes q no, never treated 5. How long has this issue persisted? When was it first noticed? PLEASE NOTE: Active infection required; no antibiotics for 7-10 days prior to swabbing. 7. What, if any, symptoms have you noticed? 8. Additional Comments: When:

7 Submitting a SAMPLE: SAMPLES: Swab the infected area and store in the recommended transport media. PACKAGING: Once swab is placed in tube, package similarly to a serum sample (cotton balls to act as shock absorber, inside a sandwich or other sealable bag, etc). Make sure to include your submission paperwork (i.e. order and history form). Attach the provided 2-day pre-paid FedEx label and call FedEx to schedule a pickup (1.800.GO-FEDEX). STORAGE: Store bacteria in the refrigerator until you are ready to ship. It is not necessary to ship culture on ice. Interpreting RESULTS... Veterinary BioFilm Susceptibility Report Veterinary BioFilm Susceptibility Report Lab Number M Patient Mayla Patry Order Date 10/30/2013 Strain ID 99.00% Staphylococcus pseudintermedius Gram Positive Breed Site Swab Clinic Name Veterinarian Pug Skin Clinique Veterinaire Vaudreuil Caroline Brazeau Lab Number M Patient Mystery Thriller Order Date 02/24/2012 Strain ID 95.00% Pseudomonas aeruginosa Sample ID Breed Site Swab Clinic Name Veterinarian Standard Dermatitis BUCKEYE VETERINARY SERVICE Meghan Kartley Antibiotics SIR Breakpoints Minimum Inhibitory Minimum Biofilm Concentration Eradication Concentration (MIC) (MBEC) Amoxicillin S: 0.25, R: 0.5 >2 R >2 R Ampicillin S: 0.25, R: 0.5 Azithromycin S: 1, R: 2 >4 R >4 R Cefazolin S: 8,I: 16, R: 32 1 S >16 R Cefovecin S: 2, R: 4 1 S >8 R Cefpodoxime S: 2, I: 4, R: 8 2 S >16 R Ceftiofur S: 2, I: 4, R: 8 2 S 8 R Chloramphenicol S: 8, I: 16, R: 32 4 S >32 R Ciprofloxacin S: 1, I: 2, R: 4 1 S 1 S Clindamycin S: 0.5, I: 1-2, R: 4 >4 R >4 R Doxycycline S: 4, I: 8, R: 16 4 S >16 R Enrofloxacin S: 0.5, I: 1-2, R: S 1 I Erythromycin S: 0.5, I: 1-2, R: 4 >8 R >8 R Gentamicin Sulfate S: 2, I: 4, R: 8 2 S 2 S Marbofloxacin S: 1, I: 2, R: 4 1 S >4 R Minocycline S: 4, I: 8, R: 16 4 S >16 R Orbifloxacin S: 1, I: 2-4, R: 8 1 S >8 R Oxacillin Sodium S: 0.25, R: R 4 R Rifampin S: 1, I: 2, R: 4 1 S 1 S Tetracycline S: 4, I: 8, R: 16 Trimethoprim / Sulfamethoxazole S: 2/38, R: 4/76 4/76 R 4/76 R Vancomycin S: 2, I: 4-8, R: 16 2 S >32 R S: Susceptible I: Intermediate R: Resistant Veterinary Biofilm Susceptibility Testing is a qualitative, in-vitro diagnostic test designed for use in determining antimicrobial susceptibility of both planktonic and biofilm phenotypes of veterinary isolates. Minimum Inhibitory Concentration (MIC) results are for planktonic cells susceptibility and Minimum Biofilm Eradication Concentration (MBEC) results are for biofilms susceptibility. Results for each individual antibiotic may be applied to other antibiotics in the same class. Brought to you by The Spectrum Group (800) FIGURE 1: These SAMPLE results indicate that there are 3 antibiotic options that can provide possible* treatment for the above infection in a biofilm state: Ciprofloxacin, Gentamiacin Sulfate, and Rifampin. The normal therapeutic dosage for a patient of this weight/size would be utilized, unless directed otherwise by your pharmacist or reference guide. Note the vast increase in suggested antibiotics using standard culture and sensitivity, In this case the patient could have been treated with 11 ineffective antibiotics. Antibiotics SIR Breakpoints Minimum Inhibitory Minimum Biofilm Concentration Eradication Concentration (MIC) (MBEC) Amikacin S: 16, I: 32, R: >32 >32 R >32 R Amikacin / Aztreonam S: 16/8, I: 32/16, R: >32/16 16/8 S >32/16 R Amikacin / Cefepime S: 16/8, I: 32/16, R: >32/16 >32/16 R >32/16 R Amikacin / Ceftazidime S: 16/8, I: 32/16, R: >32/16 16/8 S >32/16 R Amikacin / Ciprofloxacin S: 16/1, I: 32/2, R: >32/2 16/1 S 16/1 S Amikacin / Colistin S: 16/2, I: 32/4, R: >32/4 >32/4 R >32/4 R Amikacin / Meropenem S: 16/4, I: 32/8, R: >32/8 16/4 S 16/4 S Amikacin / Piperacilin / Tazo S: 16/32:4, I: 32/64:4, R: >32/64:4 16/32:4 S >32/64:4 R Amikacin / Trimethoprim / Sulfa S: 16/1:19, I: 32/2:38, R: >32/2:38 16/1:19 S >32/2:38 R Aztreonam S: 8, I: 16, R: >16 Cefepime S: 8, I: 16, R: >16 Ceftazidime S: 8, I: 16, R: >16 Chloramphenicol S: 8, I: 16, R: >16 Chloramphenicol / Ceftazidime S: 8/8, I: 16/16, R: >16/16 16/16 I >16/16 R Chloramphenicol / Meropenem S: 8/4, I: 16/8, R: >16/8 16/8 I >16/8 R Ciprofloxacin S: 1, I: 2, R: >2 1 S >2 R Ciprofloxacin / Aztreonam S: 1/8, I: 2/16, R: >2/16 1/8 S >2/16 R Ciprofloxacin / Colistin S: 1/2, I: 2/4, R: >2/4 1/2 S >2/4 R Ciprofloxacin / Meropenem S: 1/4, I: 2/8, R: >2/8 1/4 S >2/8 R Ciprofloxacin / Piperacilin / Tazo S: 1/32:4, I: 2/64:4, R: >2/64:4 1/32:4 S >2/64:4 R Ciprofloxacin / Trimethoprim / Sulfa S: 1/1:19, I: 2/2:38, R: >2/2:38 1/1:19 S >2/2:38 R Colistin S: 2, I: 4, R: >4 >4 R >4 R Gentamicin S: 4, I: 8, R: >8 >8 R >8 R Gentamicin / Aztreonam S: 4/8, I: 8/16, R: >8/16 >8/16 R >8/16 R Gentamicin / Cefepime S: 4/8, I: 8/16, R: >8/16 >8/16 R >8/16 R Gentamicin / Ceftazidime S: 4/8, I: 8/16, R: >8/16 >8/16 R >8/16 R Gentamicin / Ciprofloxacin S: 4/1, I: 8/2, R: >8/2 4/1 S >8/2 R Gentamicin / Colistin S: 4/2, I: 8/4, R: >8/4 >8/4 R >8/4 R Gentamicin / Meropenem S: 4/4, I: 8/8, R: >8/8 4/4 S 8/8 I Gentamicin / Piperacilin / Tazo S: 4/32:4, I: 8/64:4, R: >8/64:4 >8/64:4 R >8/64:4 R Gentamicin / Trimethoprim / Sulfa S: 4/1:19, I: 8/2:38, R: >8/2:38 4/1:19 S 8/2:38 I Meropenem S: 4, I: 8, R: >8 >8 R >8 R Piperacilin / Tazo S: 32:4, I: 64:4, R: >64:4 >64:4 R >64:4 R Tobramycin S: 4, I: 8, R: >8 >8 R >8 R Tobramycin / Aztreonam S: 4/8, I: 8/16, R: >8/16 4/8 S >8/16 R Tobramycin / Cefepime S: 4/8, I: 8/16, R: >8/16 >8/16 R >8/16 R Tobramycin / Ceftazidime S: 4/8, I: 8/16, R: >8/16 4/8 S >8/16 R Tobramycin / Ciprofloxacin S: 4/1, I: 8/2, R: >8/2 4/1 S 4/1 S Tobramycin / Colistin S: 4/2, I: 8/4, R: >8/4 >8/4 R >8/4 R Tobramycin / Meropenem S: 4/4, I: 8/8, R: >8/8 4/4 S 4/4 S Tobramycin / Piperacilin / Tazo S: 4/32:4, I: 8/64:4, R: >8/64:4 4/32:4 S >8/64:4 R Tobramycin / Trimethoprim / Sulfa S: 4/1:19, I: 8/2:38, R: >8/2:38 4/1:19 S >8/2:38 R Trimethoprim / Sulfa S: 1:19, I: 2:38, R: >2:38 >2:38 R >2:38 R Trimethoprim / Sulfa / Aztreonam S: 1:19/8, I: 2:38/16, R: >2:38/16 >2:38/16 R >2:38/16 R Trimethoprim / Sulfa / Ceftazidime S: 1:19/8, I: 2:38/16, R: >2:38/16 2:38/16 I >2:38/16 R Trimethoprim / Sulfa / Meropenem S: 1:19/4, I: 2:38/8, R: >2:38/8 2:38/8 I >2:38/8 R Trimethoprim / Sulfa / Piperacilin / Tazo S: 1:19/32:4, I: 2:38/64:4, R: >2:38/64:4 1:19/32:4 S >2:38/64:4 R S: Susceptible I: Intermediate R: Resistant Veterinary Biofilm Susceptibility Testing is a qualitative, in-vitro diagnostic test designed for use in determining antimicrobial susceptibility of both planktonic and biofilm phenotypes of veterinary isolates. Minimum Inhibitory Concentration (MIC) results are for planktonic cells susceptibility and Minimum Biofilm Eradication Concentration (MBEC) results are for biofilms susceptibility. Results for each individual antibiotic may be applied to other antibiotics in the same class. Brought to you by The Spectrum Group (800) FIGURE 2: These results indicate that there were no single antibiotic options available and therefore a combination panel was required. The 4 antibiotic combination options that can provide possible* treatment for the above infection in a biofilm state: Amikacin/Ciprofloxacin, Amikacin/ Meropenum, Tobramycin/Ciprofloxacin and Tobramycin/Meropenum. The normal therapeutic dosage for a patient of this weight/size would be utilized, unless directed otherwise by your pharmacist or reference guide. *unless contraindicated toll-free (800)

8 Other SOLUTIONS from Spectrum COULD IT BE ALLERGIES? Improve your success rates in allergy testing & treatment by utilizing the most advanced technology available, SPOT Platinum. Testing panels include 91 allergens & treatment up to 20 allergens, all at a fraction of what others charge. Unmatched support, turnaround & complimentary retesting on competitor s results and two options for treatment (injections or drops)! Reach beyond the gold standard & let SPOT Platinum work for you. before after before after before after L AT E AR BR ING TW RS YEA 9. 19, U8SA EST A IZON IV SPE M LA S CE E 25 RU T B C CONCERNED WITH OVER VACCINATION? UNSURE OF IF THE PUPPY PROTOCOL TOOK? Now available through Spectrum Labs, VacciCheck a rapid, in-house titer test for the 3 core canine vaccines (parvovirus, distemper & infectious hepatitis). Cost effective, easy to administer and semi-quantitative results in 21 minutes. Confirms puppy immunization success/failure. Great tool for Vet Clinics, shelters, rescues, boarding facilities, etc. 12 tests per kit, 1 yr. Shelf life. Feline version coming soon! T EN Y- F Please mail or FedEx (using our prepaid FedEx labels) all samples to: Spectrum Labs 2801 S 35th St Phoenix, AZ Have questions, need Technical Assistance or want to set up training for your office staff? Call us at: (480) toll-free (800)

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

Performance Information. Vet use only

Performance Information. Vet use only Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ... SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review (1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

AMR Industry Alliance Antibiotic Discharge Targets

AMR Industry Alliance Antibiotic Discharge Targets AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient 1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals?

Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals? Do clinical microbiology laboratory data distort the picture of antibiotic resistance in humans and domestic animals? Scott Weissman, MD 2 June 2018 scott.weissman@seattlechildrens.org Disclosures I have

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method.

Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

Antibiotic Usage Guidelines in Hospital

Antibiotic Usage Guidelines in Hospital SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The

More information

56 Clinical and Laboratory Standards Institute. All rights reserved.

56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:

More information

Antimicrobial Stewardship Program 2 nd Quarter

Antimicrobial Stewardship Program 2 nd Quarter Antimicrobial Stewardship Program 2 nd Quarter May 19, 2016 Jill Hanson, WHA DeAnn Richards, MetaStar Objectives for Today Hospital Highlight UnityPoint Health - Meriter Status of the state Update on pilot

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton

More information

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

More information

Defining Resistance and Susceptibility: What S, I, and R Mean to You

Defining Resistance and Susceptibility: What S, I, and R Mean to You Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible

More information

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience. Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY

2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY FINAL Working Group: E. Henderson, M. John, I. Davis, S. Dunford,

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens

Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Dr Pat Mitchell R & I Manager Production Stewardship APL CDC Conference, Melbourne June 2017 Dr Kylie Hewson

More information

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #116 (NQF 0058): Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS

MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS LABORATORIES ON THE FRONT LINE From the National Action Plan for Combating Antibiotic Resistant

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Chapter 2. Disk diffusion method

Chapter 2. Disk diffusion method Chapter 2. Disk diffusion method Tendencia, Eleonor A. Date published: 2004 To cite this document : Tendencia, E. A. (2004). Chapter 2. Disk diffusion method. In Laboratory manual of standardized methods

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

Recommendations to take it forward!

Recommendations to take it forward! Capacity Building and Strengthening of Hospital Infection Control to detect and prevent antimicrobial resistance in India AIIMS-ICMR-CDC EQAS Recommendations to take it forward! Top regional diagnostic

More information

- the details, where possible, of the antibiotic products these companies supply or have supplied.

- the details, where possible, of the antibiotic products these companies supply or have supplied. Under the Freedom of Information Act 2000 please could you provide me with a list of all companies currently supplying antibiotics - or that have supplied antibiotics in the last three years - to Royal

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013 Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases

More information

Measuring Antibiotic Use in NHSN

Measuring Antibiotic Use in NHSN Measuring Antibiotic Use in NHSN Jonathan R. Edwards, MStat. Research Mathematical Statistician Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases SHEA

More information

Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections

Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections Vol.1 No.2 Oct-Dec 2013 ISSN : 2321-6387 Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections S. Yogeshpriya*, Usha N.Pillai, S. Ajithkumar and N. Madhavan Unny Department

More information

microbiology testing services

microbiology testing services microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia Background The Expert Advisory Group on Antimicrobial Resistance of the NH&MRC provides advice to Australian governments and

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance

More information

CAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods

CAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods CAP Laboratory Improvement Programs Performance Accuracy of Antibacterial and Antifungal usceptibility Test Methods Report From the College of American Pathologists Microbiology urveys Program (001 003)

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Vibrio vulnificus. Vibrio vulnificus V. vulnificus. pectinata japonica)

Vibrio vulnificus. Vibrio vulnificus V. vulnificus. pectinata japonica) 2006 1 Vibrio vulnificus 1 1) 1) 1) 2) 1) 1) 2) 17 5 16 17 11 17 Vibrio vulnificus V. vulnificus 7 9 11 79 2004 11 14 (Atrina pectinata japonica) 3 11 17 16 A B 20 11 17 V. vulnificus 7 9 11 Key words:

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Using Antimicrobials Like We Want to Keep Them. Mike Apley, DVM, PhD Kansas State University

Using Antimicrobials Like We Want to Keep Them. Mike Apley, DVM, PhD Kansas State University Using Antimicrobials Like We Want to Keep Them Mike Apley, DVM, PhD Kansas State University Therapy Prevention Control Regluations Animal Medicinal Drug Use Clarification Act (AMDUCA) Regulations published

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

Available online at ISSN No:

Available online at  ISSN No: Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Color: Black/Tan NO GROWTH ON SOLID MEDIA IN 48 HRS. NO GROWTH ON SOLID MEDIA IN 24 HRS.

Color: Black/Tan NO GROWTH ON SOLID MEDIA IN 48 HRS. NO GROWTH ON SOLID MEDIA IN 24 HRS. 11/10/2015 L RD Microbiology results from Antech Diagnostics FINAL RPT 11/12/2015 PRELIM 1 11/11/2015 Ascn: IRBE51114588 Profile: Urine MIC Culture RE: 3099 SOURCE Urine RE: 3196 - (Not Stated) NO GROWTH

More information

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information